Ruxolitinib plus chemotherapy for Ph-like B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests whether adding ruxolitinib (a targeted medicine) to standard chemotherapy improves outcomes in adolescents and young adults with newly diagnosed Ph-like B-precursor acute lymphoblastic leukemia (ALL). It targets specific genetic features (“JAK-targetable signature”) thought to make the leukemia more responsive to JAK-blocking treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with B-precursor acute lymphoblastic leukemia (ALL), not T-lineage or other types.
- Your leukemia has a “Ph-like” genetic signature, and it also shows a JAK-targetable feature (like CRLF2 rearrangement or a JAK2/EPOR fusion).
- You completed a 4-drug chemotherapy induction course with medicine placed into the spinal fluid (intrathecal chemo), as your care team normally does, before starting ruxolitinib.
- You’re between 18 and under 40 years old, and you can do daily activities fairly well (ECOG 0–2).
- Your blood and organ tests are adequate (platelets >25,000; bilirubin and liver enzymes within set limits; kidney function within set limits).
- You agree to avoid pregnancy and use reliable birth control during the study (and stop breastfeeding if you are nursing); you must sign consent.
- You are not taking other investigational (research) drugs and you do not have active second cancers (except certain skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This trial tests a combination of targeted drugs (ABL/JAK inhibitors) with chemotherapy and venetoclax for people with a type of leukemia called Ph-like ALL. It aims to see if this treatment is safe and effective.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 2 study tests whether adding two medicines (ruxolitinib and chidamide) to a “conditioning regimen” before an allogeneic stem cell transplant improves outcomes for people with high-risk B-cell ALL. It may help prepare the body for transplant and reduce the chance of leukemia coming back.
This Phase 2 study tests a combination treatment for children, teens, or young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or did not respond to initial therapy. It may help patients who cannot safely receive certain standard medicines like anthracyclines or who cannot tolerate PEG-asparaginase.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.